Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast Oncology Center, associate director of the ...
Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.
Medpage Today on MSN7d
Another Win for Antibody-Drug Conjugate in HER2+ Breast Cancer With Brain MetsPFS came in at 61.6% overall, at 62.9% in those with stable brain metastases, and at 59.6% in those with active brain ...
News Medical on MSN7d
New drug shows strong activity against brain metastases in HER2-positive breast cancerA drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2 ...
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...
Trastuzumab deruxtecan (T-DXd) was effective in patients with HER2-positive (HER2+) metastatic breast cancer, with no new ...
A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach ...
Trastuzumab deruxtecan shows substantial anti-cancer activity in brain metastases in patients with HER2-positive breast cancer in major ...
A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach ...
DESTINY-Breast12 results showed that T-DXd led to overall and intracranial activity in patients with HER2-positive metastatic breast cancer. Fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) led to ...
AstraZeneca will present significant cancer research at the 2024 World Conference on Lung Cancer (WCLC) and the European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback